Ozurdex for retinal vein occlusion approved in China

The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein occlusion, according to a press release from Allergan.

Ozurdex (dexamethasone intravitreal implant 0.7 mg) is the first intravitreal injection approved for RVO in China, where there are approximately 7.4 million RVO patients, the release said.

“The approval of Ozurdex underscores our commitment to bring more innovative eye care solutions to tackle unmet medical needs in China. Coming next, Allergan China will be accelerating access to Ozurdex for Chinese hospitals — and more importantly to Chinese patients,” Shirley Zhao, Allergan China president, said in the release.

The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein occlusion, according to a press release from Allergan.

Ozurdex (dexamethasone intravitreal implant 0.7 mg) is the first intravitreal injection approved for RVO in China, where there are approximately 7.4 million RVO patients, the release said.

“The approval of Ozurdex underscores our commitment to bring more innovative eye care solutions to tackle unmet medical needs in China. Coming next, Allergan China will be accelerating access to Ozurdex for Chinese hospitals — and more importantly to Chinese patients,” Shirley Zhao, Allergan China president, said in the release.